Edison Investment Research - Solon Eiendom ASA (SOLON) Update: Vacc-4x continues to advance; next data in Q414

Report

Edison Investment Research

Update: Vacc-4x continues to advance; next data in Q414

Bionorâ€™s Vacc-4x development remains on track, with â€˜Kill & Boostâ€™ data still expected in Q414 and data from the next part of the ongoing Reduc (â€˜Kill & Kickâ€™) trial anticipated during 2015. Additional â€˜Kickâ€™ data from the Reduc study recently made a big splash at the AIDS 2014 conference. Cash should be sufficient to fund operations through completion of all ongoing clinical trials. Our valuation is increased slightly to NOK901m.

26/08/2014 4 EN

Underlying

Solon Eiendom ASA

Solon Eiendom is a biotechnology company. Co.'s focus is the research and development of peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). As of Dec 31 2013, Co.'s clinical development pipeline comprised of two vaccine candidates for the treatment of HIV, Vacc-4X and Vacc-C5. Vacc-4X is being investigated in two phases II trials in collaboration with Celgene Inc.

See profile

NO0003106700 Oslo Bors Norway

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

ABG Sundal Collier

Solon Eiendom - Terminating coverage

ABGSC terminates coverage of Solon Eiendom… …following its acquisition by SBB Last published estimates are shown in this report

January 17, 2022 January 17, 2022 1 EN

DnB Markets

Changes ahead on the new EU Green Deal White Paper

Green building-code regulations have so far targeted only newbuilds and some large renovations; however, a recent EC White Paper aims to regulate and speed up the renovation and modernisation of existing buildings. The EC is initially targeting the worst-performing 15% of building stock (requiring an upgrade from energy class G to at least F). While we expect the impact of the new regulation to be limited in our forecast period, we have raised our long-term growth assumptions and changed our sector stance to overweight (neutral).

Free Trial

January 15, 2022 January 15, 2022 1 EN

DnB Markets

Solon Eiendom (No_rec, TP: NOK) - Discontinuing coverage

Discontinuing coverage

Free Trial

January 3, 2022 January 3, 2022 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

22h / 17m 22h / 17m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN